StudyFinder

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

RECRUITING

A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.

I'm interested

ALL
18 years to 80 years old
This study is NOT accepting healthy volunteers

Inclusion Criteria:

  • Patients requiring CRRT or undergoing CRRT initiated within the prior 48 hours
  • Patients who cannot tolerate heparin or are at high risk of bleeding

Exclusion Criteria:

  • Patients weighing less than 50 kg
  • Patients receiving systemic anticoagulation
  • Patients with active bleeding

DEVICE: Niyad (nafamostat mesylate), DEVICE: Placebo (0.9% NaCl)

Acute Kidney Injury

continuous renal replacement therapy, anticoagulation

IIham IIham Boutahri - Ilham.Boutahri@cchmc.org
NA
NCT06150742
See this study on ClinicalTrials.gov

Back